Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Axsome Thera (AXSM)

Axsome Thera (AXSM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Axsome: Q2 Earnings Snapshot AP - Mon Aug 10, 6:17AM CDT

Axsome: Q2 Earnings Snapshot

AXSM : 218.20 (+1.16%)
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire - Mon Aug 10, 6:00AM CDT

Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY ® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI...

AXSM : 218.20 (+1.16%)
Axsome's Pipeline Ambitions Now Have to Show Up in the Numbers Barchart - Fri Aug 7, 4:02PM CDT

Barchart Research What to Expect from AXSM Earnings AXSM Generated August 7, 2026 Current Price $212.74 EPS Estimate $$-0.99 Consensus Rating Strong Buy Average Move 4.26% Axsome's Pipeline Ambitions Now...

AXSM : 218.20 (+1.16%)
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy GlobeNewswire - Wed Jul 15, 6:00AM CDT

FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment...

AXSM : 218.20 (+1.16%)
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 GlobeNewswire - Tue Jul 14, 6:00AM CDT

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 218.20 (+1.16%)
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) GlobeNewswire - Tue Jul 7, 6:00AM CDT

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical...

AXSM : 218.20 (+1.16%)
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) GlobeNewswire - Fri Jun 26, 6:00AM CDT

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 218.20 (+1.16%)
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month GlobeNewswire - Thu Jun 18, 6:00AM CDT

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 218.20 (+1.16%)
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 GlobeNewswire - Mon Jun 15, 6:00AM CDT

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced...

AXSM : 218.20 (+1.16%)
MarketBeat.com
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline MarketBeat - Fri Jun 5, 11:02PM CDT

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive...

AXSM : 218.20 (+1.16%)

Barchart Exclusives

This High-Yield Exchange Stock Just Raised Its Dividend by Nearly 20% Barchart - Wed Aug 19, 6:30PM CDT
Cboe Global Markets raised its quarterly dividend by 19% to $0.86 per share on Aug. 13, marking the 16th consecutive year of increases, supported by strong options trading volumes and solid second-quarter results. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.